Aidoc vs Qure.ai

Head CT hemorrhage triage is where Aidoc and Qure overlap, and Aidoc has the large independent study for it. A real-world study of Aidoc BriefCase across 101,944 head CTs at 17 facilities reported 82.2% sensitivity and 97.6% specificity, dropping to 45.5% for subacute bleeds, 54.8% for chronic ones and 74.8% for bleeds of 10 mm or less. Qure's qER was cleared as CT triage in June 2020 (K200921). Its independent evidence sits on the chest X-ray side, where qXR v3 reached 95.5% sensitivity at 48.7% specificity for TB in a 12-product evaluation, at a single threshold.

Aidoc's modules cover CT triage, quantification, cardiology and neurovascular care, listed on AWS Marketplace at $6 per scan per algorithm per hospital site on a 12-month private offer. That suits an emergency CT worklist and gives a national TB program no reason to start there. Qure reports a WHO endorsement from 2021 for TB screening on chest X-ray, and the sources show no FDA clearance for Qure's TB screening, so Qure drops out for a US hospital that needs a cleared TB tool.